CALCIUM/CALMODULIN DEPENDENT KINASE AND AN ALTERNATIVE SPLICE PRODUCT THEREOF

Abstract: The present invention provides novel means and methods for regulation of calcium/calmodulin dependent processes. In particular the present invention provides a novel kinase CaMK VI and a peptide involved in feedback of CAM kinases, named CARP.

Description: CALCIUM/CALMODULIN DEPENDENT KINASE AND AN ALTERNATIVE SPLICE PRODUCT THEREOF Introduction. The present invention relates to the field of cell biology and particularly to physiological changes occurring in cells and thus in organisms as a result of a change in calcium concentrations in the cell's environment. A group of molecules that is involved in the regulation of, or affected by fluctuations in calcium concentrations is the group of calcium/calmodulin dependent kinases . These kinases play pivotal roles in many of the cell's processes and are thus also pivotal in many disorders. One of these disorders to which tfhis invention specifically pertains is epilepsy. Epilepsy is characterised by transient disturbances in brain function that is manifested as episodes of unconsciousness, abnormal motor patterns and physiological or sensory disturbances and affects approximately 1% of the human population. Many factors, e.g. brain damage, altered metabolic states, drug abuse, have been shown to cause epilepsy, but it is generally accepted that all these converge into a distortion of the neuronal excitation- inhibition balance. This disbalance subsequently triggers recurrent episodes of aberrant synchronisation in specific neuronal networks, in particular in the cortical layers and in the hippocampus resulting in epileptic seizures. A number of well-established animal model systems, including kainate-induced seizures, have been used to study the electrophysiological, biochemical and molecular biological mechanisms underlying epilepsy. Studies in these systems have implicated an aberrant calcium-activated kinase activity as the major factor for the induction and onset of epileptic seizures. First, several anti-epileptic drugs are thought to target calcium channels directly or indirectly {Stefani et al., 1996, von Wegerer et al . , 1997}. Second, induction of epileptic seizures in several model systems seem to alter the expression of calcium-activated kinases. For example, the calcium/calmodulin dependent protein kinase (CaMK) -II mRNA, the cellular localisation and activity of the CaMK-II protein are changed during kindling and continuous hippocampal stimulation-induced seizures {Morimoto et al , 1997; Perlin et al . , 1992; asterlain et al . , 1992}. Third, numerous immediate early genes which are activated by calcium- dependent kinase pathways are induced or upregulated after kainate or kindling-induced seizures . {Gass et al . , 1994; Gass et al., 1997; Herdegen et al . , 1993; Herdegen et al . , 1997; Hughes et al . , 1998}. Fourth, mutations in several genes with relevance for neuronal calcium-activated kinases have been shown to cause epileptic seizures in mice (reviewed in McNamaia and Puranam, 1998) . For example, targeted deletion or aberrant splicing in the calcium channels and in CaMK-II genes will induce an epileptic phenotype in mice. Together, these data strongly favour a model in which calcium-activated kinase mediated signal transduction pathways affect the onset and course of epileptic seizures. In humans only a few genes have been identified which are associated with genetically predisposed forms of epileptic seizures. Recently, mutations in a novel gene, doublecor in, have been associated with the human X-linked lissencephaly and the doublecortex syndrome {des Porte et al . , 1998; Gleeson et al . , 1998}. This disorder is characterised by malformation of the cerebral cortex and will produce severe mental retardation and seizures {Dobyns and Truwit, 1995}. Doublecortin shares a high degree of amino acid sequence identity over its entire length with the amino terminus of a novel CaM kinase, called KIAA0369 {Nagase et al . , 1997}, but doesn't contain a kinase domain itself. It was speculated {Gleeson et al . , 1998} that the malfunction of the doublecortin protein will lead to aberrant modulation of protein kinase-mediated signal transduction pathways which might underly the morphological and behavioural epileptic phenotype. In combination with the above, these data suggest that malfunctioning of calcium-affected kinase activity is crucial for the onset and maintenance of epileptic seizures. The present invention provides in one embodiment identification and characterisation of a cDNA which is highly induced by kainate-induced seizures. The corresponding transcript is generated by alternative splicing of a novel CaMK gene, another embodiment of the present invention. The cDNA encodes a 55 amino acid peptide, called CaMK-related peptide (CARP) and plays a role in kinase-mediated neuronal plasticity which is associated with the course of epilepsy. A large part of CARP, 48 out 55 amino acids, is highly homologous with the carboxy-terminus of the recently characterised human doublecortin. Mutations in the doubleαortin gene have been shown to underly the molecular mechanism leading to X-linked lissencephaly and the doublecortin syndrome {des Portes et al . , 1998; Gleeson et al . , 1998}. These disorders are caused by a migrational arrest of cortical neurones to their destination which lead to a malformation of the cortex and are further characterised by severe mental retardation and epileptic seizures {Dobyns and Truwit, 1995}. As doublecortin is a likely substrate for members of the MAP kinase family, it was suggested that doublecortin transduces signals which are critical for migrating neurones {Gleeson et al . , 1998}. The homology of CARP with doublecortin and the conservation of some of the phosphorylation sites show a similar role for CARP in the neuronal plasticity. Seizure activity has been shown to result in massive reorganisation of synaptic contacts, neurogenesis and affects neuronal networks in the hippocampus, in particular in the dentate gyrus {Buckmaster and Dudek, 1997; Mathern et al . , 1996; Parent and Lowenstein, 1997; Parent et al . , 1997; von Campe et al . , 1997}. Our findings that CARP is specifically induced in the hippocampus after kainate-induced seizures and that this induction is most pronounced in the dentate gyrus, is well in line with this function of CARP. Seizure-induced CARP expression may act as a substrate for hyperactivated kinases, although the invention is not limited to any possible mechanism of action of CARP. At the protein level, CARP overlaps with CaMK-VI at the extended, serine- rich N-terminus and has no overlap or ho ology with the catalytic or regulatory domain. This implies a function of CARP which is directly linked to that of the serine rich N- terminus of CaMK-VI. In this respect, the structural similarity of CaMK-VI to CaMK-IV is of interest. In contrast to other CaMK's both the rat α- and β-CaMK-IV also contain an extended, serine-rich N-terminus {Sakagami and Kondo, 1993; Means et al . , 1991}. Full activation of CaMK-IV involves at least tshree steps: firstly, calcium/calmodulin binding will lead to exposure of the catalytic domain to a CaMK-IV kinase; secondly, phosphorylation of Thr214 induces kinase activity and thirdly, auto-phosphorylation of several serine residues in the N-terminus occurs (for review see {Means et al . , 1997}. Mutation of both Serl2 and Serl3 into alanine residues in a-CaMK-IV completely abolishes the kinase activity. Moreover, removal of the N-terminal 20 amino acids results in a kinase with wildtype CaMK-IV properties. This indicates an auto-inhibitory function of the N-terminus which can be relieved by auto-phosphorylation {Chatila et al . , 1996}. The structural resemblance of the presently invented CaMK-VI with the extended serine-rich N-terminus of CaMK-IV and the presence of several phosphorylation sites in both CARP and CaMK-VI suggests a similar, 3 -step activation mechanism for CaMK-VI, implying that phosphorylation of N-terminal located serine residues is crucial for full activity. Accordingly, CARP functions as a modulator of CaMK-VI and/or other kinases . CARP is likely derived from a gene which gives rise to a number of splice variants encoding different peptides and/or proteins involved in kinase-mediated signal transduction pathways. Beside CARP, transcription of this CaMK gene leads to a CaMK which we have called CaMK-VI . Over its entire length, CaMK-VI shares 99% amino acid sequence identity with the carboxy-terminus of predicted 750 amino-acid long human protein encoded by a cDNA clone called KIAA0369. Thus, it appears that the predicted KIAA0369 protein is an extended human homologue of CaMK-VI and this suggests that the gene encoding CARP/CaMK-VI may also generate a transcript encoding a rat extended CaMK-VI protein. Indeed, a rat DNA sequence encoding the amino-terminus of KIAA0369 has been deposited in Genbank (accession NR AA818566) . In addition, the multiple CaMK-VI transcripts observed in our Northern blot analysis are well in line with this notion. Interestingly, the predicted 360 amino acid long doublecortin protein has a high degree «of amino acid sequence identity (70%) with amino- terminal part of KIAA0369 but lacks catalytic kinase domain {des Portes et al . , 1998; Gleeson et al . , 1998} (see also Figure 2B) . Thus, in human at least two related genes, doublecortin and KIAA0369, are present which encode proteins involved in kinase-mediated signal transduction. As both doublecortin and CARP are associated with epileptic seizures it shows a pivotal role of this gene family in epilepsy- related neuronal plasticity. CARP mRNA is induced by kainate-induced seizures. In contrast, CaMK-VI isn't upregulated in these same animals. This CARP-specific induction is thought to be the result of a negative feedback loop aimed at turning off kinase activity. It is very well conceivable that calcium overload in a cell - triggered by kainate-induced seizures - leads to activation of different CaMKs and/or other kinases. This enhanced kinase activity induces CARP expression which subsequently acts as a modulator of this kinase activity, e.g. by acting as a substrate or by irreversible binding to activated kinases. Thus the invention provides in one embodiment a novel mammalian calcium/calmodulin dependent protein kinase (CaMK- VI) and its encoding sequence, which kinase in the rat comprises the sequence MLELIEVNGTPGSQ STPRSGKSPSPSPTSPGSLRKQRISQHGGSSTSLSSTKVCSSMDEN DGPGEEESDEGFQIPATITERYKVGRTIGDGNFAWKECIERSTAREYALKIIKKSKCRGK EHMIQNEVSILRRVKHPNIVL IEEMDVPTELYLVME VKGGDLFDAITSTSKYTERDASG MLYNLASAIKY HSLNIVHRDIKPENLLVYEHQDGSKSLKLGDFGLATIVDGPLYTVCGTP TYVAPEIIAETGYGLKVDI AAGVITYILLCGFPPFRGSGDDQEVLFDQILMGQVDFPSPY DNVSDSAKELINMMLLVNVDQRFSAVQVLEHP VNDDG PENEHQLSVAGKIKKHFNTGP KPSSTAAGVSVIAPDHGFTIKRSGSLDYYQQPGMY IRPPLLIRRGRFSDEDATRM or a specific and/or active fragment or derivative thereof. The sequence of the homologues of this rat kinase can of course be easily obtained by priming or other techniques in the art. For specific applications different parts of the sequences may be relevant and those parts alone are of course also part of the invention, as are derivatives of the original sequences, wherein several replacements of amino acids or the corresponding codons or basepairs can be made without changing the function of the kinase (at least without changing the kind of function, the rates of function can of course be affected (enhanced or deminished) . Usually such changes can be made for changing e.g. the stability of a resulting encoded product. The product encoded by the nucleic acid or a degenerated variant thereof is of course also part of the invention. Thus in another embodiment the invention provides a mammalian protein kinase which is at least partially encoded by at least a specific part of the following DNA sequence; CTCTGGCTCTTGGCTATTGTCAGGTCAAACACTAAGACTGTGTCCATGTTAGAACTCATAG AAGTTAATGGAACCCCTGGCAGTCAGCTCTCCACTCCGCGCTCCGGCAAGTCACCAAGTCC ATCGCCCACCAGCCCAGGAAGCCTGCGGAAGCAGAGGATCTCTCAACATGGCGGCTCCTCC ACTTCACTTTCATCCACAAAAGTCTGCAGCTCAATGGATGAGAACGATGGCCCTGGGGAAG AAGAGTCCGACGAAGGTTTCCAGATTCCTGCCACAATAACAGAGAGATACAAAGTCGGGAG AACAATAGGAGATGGAAATTTCGCTGTTGTCAAGGAATGTATAGAGAGGTCGACTGCTCGG GAGTATGCCCTGAAAATTATCAAGAAAAGTAAATGCCGAGGCAAAGAACACATGATCCAAA ACGAGGTCTCCATCTTAAGGAGAGTGAAGCATCCGAACATTGTTCTCCTGATTGAAGAGAT GGATGTGCCGACTGAACTATATCTTGTAATGGAGTTAGTAAAGGGTGGAGACCTTTTCGAT GCCATCACTTCCACTAGCAAATACACAGAGCGGGATGCCAGTGGGATGCTGTACAACCTGG CCAGTGCCATTAAATACCTGCACAGCCTGAACATCGTCCATCGTGACATCAAGCCAGAGAA CCTGCTGGTGTATGAGCACCAGGATGGCAGTAAGTCACTCAAGTTGGGTGACTTTGGCCTG GCCACAATTGTCGATGGCCCCCTGTACACAGTCTGTGGCACCCCAACTTATGTGGCTCCAG AAATCATTGCAGAGACTGGATATGGCCTCAAGGTGGACATCTGGGCAGCTGGCGTGATCAC TTATATCCTGTTGTGTGGTTTCCCTCCATTCCGTGGAAGTGGGGATGACCAGGAGGTGCTT TTTGACCAGATCTTGATGGGCCAAGTGGACTTTCCATCTCCGTATTGGGACAATGTGTCAG ATTCTGCTAAGGAGCTCATCAACATGATGCTGTTGGTTAACGTGGACCAGAGATTTTCAGC CGTGCAAGTCCTTGAGCACCCCTGGGTTAACGATGATGGCCTCCCAGAAAATGAACATCAG CTGTCAGTAGCTGGCAAGATCAAGAAGCATTTCAACACGGGCCCCAAGCCGAGCAGCACGG CAGCTGGAGTTTCTGTAATAGCACCGGACCACGGGTTTACCATCAAGAGATCAGGGTCTTT GGACTACTACCAACAACCAGGAATGTATTGGATAAGACCACCGCTCTTGATAAGGAGAGGC AGGTTTTCCGACGAAGACGCAACCAGGATGTGAGGGGCCGGTACAAGGCACAGCCAGCTCC ACCAGAACTCAACTCGGAATCAGAAGACTACTCCCCCAGCTCCTCTGAGACTGTCCGCTCC CCCAATTCGCCCTTTTAATAAGACCCCTTCACTCGAAGTCCTAGCTTAACCCTTTAAGACT CTGAGAΈTCCCCCTCCCCCCAAACTTCTGTAAAACAGGTTCATCTGATCTACCTAGCACTC AGTGCTGAACGGCAGAACAGAAAGTATATTTCGGGTACCTTTGTAGCAAGTTCCCTTTACT GAATGAGAAGGCATGTGGTGTTTGTGACAACGGTAATTTGCTGCTAATAGGGGTCCTTAAA GGGTTGAGGCTAATTTGCGATTTTTTTTCTTTTAACATAGAAGTAACGAATGTTTTCATCA GTCAGACTAGGATCTGCAGTATGTAACATAGCACATGTTAGCCCTCTGAGTGCATAGAATT TGCTTGAGAATCCTTGCTGGGGAATTTTTCAGACCCTTGAGTGTATTCACACATATTTCTT GATTTTACTGCAGACCAAGGGGCGTCATTGAGACCCAAAATGTCCACCCAAGAAGAGTATT GGGGAATGACACATTGCCAATTCTTCTCAGTGGGCTTAGACAATGACGGGTTCTACAGCAT CAGCAGATGCACCCCTCCTTCTTAGCCATCTTATGAAGAAGGGAAGTCCCTTTCCCTACAT AGTAAGCTGCAGAGCCTTCTCTGCTCTGATTGGAGGGAGTTAAGGTTTGTGGCTGCCTATC CCAAGTGATCGACAGTGTCTCTCC Of this nucleic acid derivatives and/or fragments as meant hereinbefore for proteins are of course also included. A derivative and/or fragment will have the same or similar function and/or structure (in kind not necessarily in amount) in the resulting product. As disclosed herein the gene encoding the novel kinase has an alternative splice product involved in feedback. This is of course also an embodiment of the present invention, both on the nucleic acid level and the protein level, which can be applied in feedback of any kinase related to the presently invented kinase. Thus in another embodiment the present invention provides a mammalian calcium/calmodulin dependent protein kinase related peptide (CARP) which in the rat has the amino acid sequence MLELIEVNGTPGSQLSTPRSGKSPSPSPTSPGSLRKQRDLYRPLSSDDLDSGDSV and in the mouse MLELIEVNGTPGSQLSTPRSGKSPSPSPTSPGSLRKQRDLYRPLSSDDLDSVGDSV or a derivative or a specific and/or active fragment thereof. Here derivatives and/or fragments are intended in the same manner as hereinbefore. Homologues in other species or alternative splicing products of reated kinases can now easily be produced according to the invention. As stated the product of this alternative splice product or its copy is also provided. Thus the invention provides a mammalian calcium/calmodulin dependent protein kinase related peptide (CARP) which is at least " partially encoded by at least a specific part of the following DNA sequence GGCTATTGTCAGGTCAAACACTAAGACTGTGTCCATGTTAGAACTCATAGAAGTTAATGGA ACCCCTGGCAGTCAGCTCTCCACTCCGCGCTCCGGCAAGTCACCAAGTCCATCGCCCACCA GCCCAGGAAGCCTGCGGAAGCAGAGGGACCTGTACCGCCCTCTCTCGTCGGATGATTTGGA CTCAGGAGACTCAGTGTAAAAGACACAGTGGAGCGATGTGTATGGTTTGTGATGGGATCAA GGTTTCCCATTTCCTAAGCAAGCATCTAACAGCAAAATACACAAAAGAGTTTTGCATAAGC AATTAAATTATACAAAAGCAAGAGTGCAGACATTTTCTACTCGGCGGTATTCTTTGAAAGA AAAAAAAAACTTTTTTAAAGCATCTCCTCCATTTGATGTAACCGAGGAGAGTTTGAATACA ATATTTGTTCATCACTGAGGATTTTATGACTAAGGTCTGGTTCCAGATAAATTTCATATAT GACTCCAATATTAAGTACAAGAATCACCCTAACGATCCAGCATTATGGAGTCACCATTTCT ATAAATGAGCCTGCTTTTTAATCAGTAAGTAGATATATAAATACAATTTTTCTGTACTTAG TATCTTTTACCTTTTTAGTTTAAATTTTTTAAAAAAATCAGACAGCTAATTAGTTATTTCA TTGCAAAATAACATAAAAGAATCTCTTCAGGATTTTTTATTTGAGTGAATACGTCTGAAGG GGAGTGGAGGAACTCCGTAAGAGACGTCTCCCAGAGACCAACATTAGGCAGCGAGAACGTT TCTGGTTTTTTTTTTTTTTTTTTTTGTTTTTGTTTTTTGCCACATGGATTTTCTTTTCCCA GATTTTTATAAAAATAGTTTCAACTACATGGAAACATGAATAACTTGGCATTATTATTAAT TTTATAATGGTTCCCAACAGCAACAACAGTATATATATCTTTTTCAAGTGTGTAAAGTTTT TTGACCTAAAACAAATGGGACTTGTACTGTTTTTCAAAAAATAAACTCAGTTTGAGAATTG GAATTCTTCTACACAGAGCTTGTACGTTGGGCCTCCAGGTAGCTAAACTCCATTCTGATCA TCCTGCATCCCGTTGTTTGGGATATCTTCACATGCAAAACTCCTTTTGTGTCAAACCGAGT GTGTCTATGATTATAACCCACTGTTAAAATTAACCTACTAATTCTTCTCCTTTAGTCCTCT ACTTTCAAAAGCGTGAGTCAGCTTTGCTTAAATGTAAAACAGTTATTTTTTAAATCTAAAT GTTAGAAATCAATGTGTACGGTGTATTGTATTTAGACCATACCCGTGACCGTTTCTTTTTA CTAGCTCAAACACTAACAATTTAAGACTTACAAAGACATGGGTTTTATATTCGCCAGGCTT GACATATCTCAGTAGGGTGACAGATTTAAAATGTATGGTGCCATTTGGAGCCTTTTACTTG AGATTTCTTTCAAATTTCACTTGAAAACATTTTGAAAATGCCTGATTCAAGATGGAGAGGA GTCGCCTTGTCATACGGTCTCAAATGTTATTGATTTATTTCTCTCAGTAGACTGTTCGACT AGCAATTTTTCCCATCTGGTTTATCGTTACCTGTGCTAGCATCTCACTTGACAAGTGAATA AAATATTCCAACTGAAAAAAGAAAAATAAGACCTCCAGGCAACCTACCAGCATTTGAAAAG TTAGCCGAGTGATAATTAGTGCCTCATAACCCTGCCTGTTAGAGAGGAGAGGGCACTTCTT TGGCGTGTTATTTGAGAACTGCAGACTGATCCCTCCATCTTGAAAGCACAGAGAATGATCA TACCTGTTCCAGACTTCGGATTTTAAAACTGTTTCCAATAGACACGAACAGAGACTCCTGC TGAGATCAAAGGGCCGCTTTGTCTTTAGCTGAAACAGTAAACATCTGGGAGGATGCTGTGC TGCCTGTTGGAGTGTTACGTCTTTGTAAGATGCATTGCTTAATATAGTCCAACCCGTAAAA GATTAGTACAGATTTGACTAACCTGTCAAAAAATGCAATGAAAGCAGTGGGTCAGATGGTC CAGAACA^AACATAAATTCCAGTAATTTCAACTCCCCTATGAAGTCAATCTTATGGACGAC TACTGCTAGGAGAAACCTAATAAATGTTATCTGCTATAAAAATCGTGGCTTTGTTTAGACA CAGCATAGAGTAGACTTGGACTAATTGCCAGTAGGTATTGTGGCCAACTTTCCATTCAAGC AGTTCCAGAGAGATGCAATCCCATGGCATTTCATCCTGGAACATACGATTTTTATTAAAGG ATTGTTCAAGGGCCATATATCTCATTTACTTTTGAAACTAAAGTCCCTCTGAGATTGAAAC AACACACCCTGAGATCTCTTTCTATGCACGGAATAATTCTATTATCCAAAAGCAGAGTTTT TGAACATCCAAGCAGCCCACCAGGTCATTAGTAAAGACCCAATGGGCAATTAGCAGTCACT CAAGACGTGGCTGCTTTTAGAATCCTTCTAACATCATTAGTCGCTGAACTCTAAAAATGAC CTTCTGAGGAAAGAGCTCCAGCCAACAAAAGCCACATGCTTTTCTCTCACTGATAAAGCCT CTGCTGTGTTGACCTTTCAGGCCTTTGCATGTATGGTTACATTTTTTTAGACATACCTAGA AAGAAAGATGCTATAAAGAGTCCCCTGCTTTCAGCATTTTATGAGCTAAAACCCTAGTGAT GCACAAAATGTGTTGCTCTGCGTGAACTCCGAAGCCATGTGGGAAAGTCATTGTCATTTCA GCAGAAGGTCTGTACTCTTGTAGGTTTCTAAACCGGAAGTTTGTGCTCCACCTATATGTAC GCATGCCTGCAATGCACACATGAGGTCACCTTAACATGTCAAGATCTGATCCCGTTGTCTG CCAACCCCAGAGCAGCTCTGACACCTATGCTCCCCTGCCAAGCAGCGAGGGCACTCGCCCT CCCCTTCCTTGCAGCCGCACCGAGCTGTACTTTTGTTTCCATTTAAAAGAACTGAATTCCA AAAGCCTCGTTTTAAAAAAGCAATTGGGAATGAAAATACATAAGAATAATCCTAAAAGATA AATCCATATATTTAACCTGTTGAACTACTAGGTTTTTTTTTTCTTTTCCTGGTGGCCATAT ATCTATACAGGTGTGTAGGTGTGCCTA CATGAATATCTGTGTTTGTATATAGAACATGAAGAATAAAGGATGATATTTGTGATATGGT CTTATAAGTTACTGGCTCCTGTAGAATTAACTGTGAAGCTTTATGTGATAAAGTTGTGACG TATGTATTAGTTGGCACATGTTTAAGCTCAAAACAAGTTGGCTAAATTATCATGAAGCAGT ACCAACTGTTCACGGGTACGAATTTATCCAAGACCGATTGGAATCCAGACAAACAAAAAAA TTGAAGTCCAAGCAAATCCAATCTTACAGTGATTGATAAATGTAAATACTCATTGATGTTT TCACTGTAAATTCTTGATGCTCAGCCAGTAATCTGACAGAATGCAGTGACACTTTCCTGTT GTGTGTGTACTGATGACTACAGCGATTATCAATGGGAAATTCACCAAACAAACTGATTTCT AGACTTGTGGACAGTTGAGTGTTTGTGCTGAAATAAAAGTAGAAAAGGTCAAAGTAAATTC GGTTTGAAGCCTTGTTATGAAGCCAGACAACATGTAAGGCCATGCTGTGTGTCCTTTTTAT AAACTGTTTTGGAGACACTTGCTGTGTGTGTGCATGTGTGTCTACATGAGTGTATACACAC TTGAAAATGCTTATTGACTCAAGTTCACTGTCTGTATACATCTGTGCCTATCTGCATTGGT CTGGCCAGCGCCTCTAACTGTGCATGGTAGTGACAGCCCTGTGTGATTGGATGAACCCACA GAAAAATAGTGTGGAAATCAGAGCTGCGTCAAACTCATTATAACAATTGCCTGATATAGCA TATTAAATTGTCAGCTGAAAAACGTTTGTAATGTTGTGCCTGTAACATGTGTAGGGAAAAC TGGAAAATCTGAGGCCCTCACTATAATTTTAAGGGTGCATGACATGTGGTGTCTTTAAAGA TGTATCTTATTGTAATAAAAGGTGATGGATAAATTCTGAGGTAGCGTAAGTGAAGCATGAA ACGCTAGGTGTTTGTATTATATATGGCCACACAATATTTTTGAAGGCAGGGTAGTAAATGT TTGAAGGΓTTAATAGGCAAAGAATATGGAAGTTAATTTTACTGTGATGTGTTTTTGAGGTGT TTTACACATTGCCAGACAAGGAACTTAGTTCCTGTTTCCCCCCTGGGACTCTTTGAAACAC TATGAATGTTACAAAGTTGGATTTTCTTTATAAAGGTCGCAAACCATTTGCAGTTGGAGTT GCTTGGATGTATAGTCTCCTCTTTGGGGAAAAAAACCACTTTGGTATTAAAATGGTTTAAG CACTAATACATTGGGAAATACGTCGTCTGAGGCCATCTGCAGACATCTGTAGAGATGAGAA CTAATGAAATGTGTTACTGAACTACCCAGTTTTGATAGCTTCCATGCCTCTCTGCTGTAGT CTCCTCGAAAATGCTGTACCTTGTGTTTCACATGCAACCATGTTACTCTCTCCCGAACTTA CCTTTGTGACACTTAGCAGCTTAGCCAAACCACGTAATAAACAGGAAGAACTGCCAAAAAA AAAAAAAAAAAAAAAAAAAAAA As stated the invention also provides a recombinant and/or isolated nucleic acid molecule encoding at least a specific and/or active part of a mammalian calcium/calmodulin dependent protein kinase (CaMK-VI) and/or a recombinant and/or isolated nucleic acid molecule encoding at least a specific and/or active part of a mammalian calcium/calmodulin dependent protein kinase related peptide (CARP) . Also part of the invention is a cloning and/or expression vector comprising an isolated and/or recombinant nucleic acid molecule as provided above. Also part of the invention is a mammalian host cell comprising a recombinant and/or isolated nucleic acid or a vector as represented above. Typical applications of the molecules or their precursors according to the invention are the treatment and/or prevention of seizures and/or damage to the central nervous system, in particular the hippocampus. In general the invention provides a method for down regulating calcium/calmodulin dependent protein kinase activity in cells comprising providing said cells with a mammalian calcium/calmodulin dependent protein kinase related peptide (CARP) according to the invention. Our invention is relevant for a number of diseases. Acute brain insults as stroke, trauma, hypoxia, ischemia, but also some neurodegenerative diseases such as Alzheimer are associated with high local concentrations of excitatory amino acids, in particular glutamate. These glutamate concentrations will lead to excessive Ca2+ influx and consequent activation of numerous calcium-dependent kinases which will ultimately lead to cell death and thus neurodegeneration. As a consequence, glutamate is released by these dying cells which, in their turn, will threaten neighbouring cells by introducing excessive calcium in the cytoplasm (for review see Pettmann and Henderson, 1998) . As CARP is capable of down-regulating calcium-dependent kinases, this self-propagating cell-destruction programme, associated with the diseases mentioned above, is likely to be blocked by CARP and thus, excessive neurodegenerative processes can be prevented by CARP treatment. In addition, the induction of proliferation of T-lymphocytes has been associated with activated CaMK-IV (Gringhuis et al , 1997; Marklund et al, 1994) which, of course, can be also be blocked by CARP. Thus, certain forms of leukemia, which are characterized by aberrant T-lymphocyte proliferation may be blocked by CARP. The action of CARP is tested in the following models: 1. Different cell lines, i.e. the neuronal cell lines PC12 , HT22, H19 cell as well as several neuroblastoma cells and several non-neuronal cell lines such as Jurkatt cells, derived from lymphocytes will be challenged with apoptosis- inducing agents . The rate of apoptosis is monitored by biochemical means such as DNA laddering, histological means , i.e. TUNEL staining, FACS scanning etc. and compared with the reduced rate of apoptosis in which CARP is overexpressed by means of transfecting cells with expression plasmids pcDNA 3.1 containing CARP in a sense orientation. 2. Synthetic full length CARP peptide is used to manipulate the activity of purified MAP kinases, CaM-kinases and other calcium-dependent kinases in an in vi tro kinase assay (see e.g. Veeranna et al , 1998) . Treatment of patients with with acute brain insults mentioned above, will occur by local i.e. . administration of the CARP peptide^, by local expression of CARP via viral infection of recombinant adenoviruses containing the CARP construct, or by development of agents which induce endogeneous CARP expression. Leukemia can be treated by intravenous administration of the CARP peptides or modifications thereof. The invention will be explained in more detail in the following detailed description. Detailed description. Materials and methods Animal treatments Young adult male Wistar rats (180-200 g) from Charles River were housed under standard light conditions; 12 hr. light/dark cycle with free access to food and water. Eight mg per kg body weight kainic acid was administered intraperitonially. Control treatments consisted of administration of vehicle solutions only. Three hours after injection, the rats were decapitated, the brains were dissected and immediately frozen and stored at -80 "C until use. All animal experiments were conducted according to the European Communities Council Directive 86/609/EEC. The protocols were approved by the animal Care Committee of the Faculty of Medicine, University of Leiden, The Netherlands (UDEC no 9569) . Isolation of full -length CARP cDNA clones and a partial CaMK- VI cDNA clone . • A CARP cDNA fragment, generated by differential display (DD) and induced by adrenalectomy and kainic acid administration {Vreugdenhil et al . , 1996} was excised from the nitrocellulose membrane, eluted and subcloned in pGEM-T (Promega) according to Engels and Vreugdenhil (manuscript in preparation) . DNA sequence analysis was performed using a ABI 377 automated sequencer and a Dye terminator cycle sequence kit (Perkin Elmer) according to the instructions of the manufacturer. Based on the DNA sequence obtained, synthetic oligonucleo ides were synthesised (Perkin Elmer, Nieuwerkerk a/d IJssel, the Netherlands) and used in the marathon cDNA amplification kit (Clontech) , which is a modification of a polymerase chain reaction (PCR) -based strategy called Rapid Amplification of cDNA Ends {Frohman et al . , 1988}. PCR- fragments were size-separated on 1.2 % agarose gels, blotted and hybridised with 32 P-labelled oligonucleotides, designed from internal DNA sequence of the DD fragment. Positive PCR- fragments were excised from the agarose gel and analysed directly by DNA sequence analysis or first subcloned in pGEM- T (Promega) . DNA sequence analysis was performed by a "DNA walking" technique towards the 5" end and 3' end of the transcript using synthetic oligonucleotides derived from novel DNA sequence information. This strategy resulted in a final stretch of 4746 nucleotides. The identity was verified by the complete amplification of this sequence using extreme 5' and 3' synthetic oligonuceotides and by Northern blot analysis. This sequence has been deposited to Genbank and is available under accession NR AF045469. The CaMK-VI cDNA clone with a length of 2031 nucleotides was isolated and characterised by PCR using an oligonucleotide 5' -CTCTGGCTCTTGGCTATTGTCAGG-3 ' derived from the 5 ' end of the CARP cDNA clone and an oligonucleotide 5 ' - GGAGAGACACTGTCGATCACTTGG-3' corresponding to position 2092 to 2115 of Genbank entry accession NR U78857. The resulting cDNA fragment was cloned in pGEM-T and analysed by DNA sequencing. Northern blot analysis Total RΝA was isolated from rat hippocampi using TRIzol^M (Gibco-BRL) according to the manufacturer's instructions. Total RΝA (approximately 20 μg per lane) was size-separated on a _f% formamide gels and blotted onto Hybond-Ν filters according to standard methods {Sambrook et al . , 1989}. Filters were hybridised 0/Ν at 65 °C in buffer containing 0.4 M Νa2HP04, 0.1 M NaH2P04, 7% SDS and ImM EDTA. Filters were washed at 68 °C, twice in 2xSSC/ 0.5%SDS, and once in 0.2xSSC/0.5%SDS. Each wash step was performed for 10 min. Filters were exposed to Kodak X-Omat AR films for one week. To correct for differences in RNA levels and RNA quality, filters were reprobed with a glyceraldehyde-3 phosphate dehydrogenase (GAPDH) probe. Hybridisation, washing and exposure was performed as described above . 32 DNA probes were labelled with P α-dCTP using the multiprime DNA labelling system kit (Amersham, England) according to the manufacturer's instructions. A CARP probe was prepared by RT-PCR amplification of a part of the 3 ' - untranslated tail (bp 880 to 4657) with synthetic oligonucleotides 5 • -CATGGAAACATGAATAAC-3 ' and 5 ■ - CGGGAGAGAGTAACATGG-3 ' using hippocampal cDNA derived from a kainic acid-treated rat as a template. A CaMK-VI probe was prepared by PCR amplification of the middle part of the coding region encompassing bp 769 to 2040 by using synthetic oligonucleotides 5 ' -AGTCTGTGGCACCCCAACTT-3 ' and 5 ' - GGAGAGACACTGTCGATCACTTGG-3' and using the cloned CaMK-VI cDNA (see above) as a template. A GAPDH probe was prepared by PCR amplification of residue 149 to 515 corresponding to EMBL database entry NR X02231 by using synthetic oligonucleotides 5'-GACATTGTTGCCATCAACGACC-3' and 5 ' -TGCATTGCTGACAATCTTGAGG- 3', using hippocampal cDNA described above as a template. All resulting DNA fragments were gel-purified and their identity was verified by DNA sequence analysis of both ends. Hybridisation signals were quantified using an Olympus image analysis system (Paes, The Netherlands) , equipped with a Cue CCD camera. The film background was subtracted after shading correction. In si tιι hybridisation In si tu hybridisation experiments were performed according {Meijer and de Kloet, 1994}. Briefly, serial coronal sections (20 μm) were cut through different brain regions. The sections were thaw mounted on poly L-lysine coated slides and stored at -80°C. Hybridisation was performed using the CARP- specific 180 bp cDNA fragment, identified by DD. This fragment corresponds to bp 3268 to 3443 and doesn't overlap with CaMK-VI. This fragment was polished using Pful DNA polymerase (Stratagene) and ligated in the Srfl site of the vector pScript (Stratagene) . Both the sense and the antisense cRNA probes were generated using S labelled UTP and T7 or T3 polymerase. For hybridisation, 100 ml of a probe with a concentration of 2,5xl0 7 cpm/ml was used. The sections were exposed for seven days to a Kodak X-OMAT AR film. Results We have used the differential display (DD) technique to identify kainate-responsive genes which are under the control of corticosteroids {Vreugdenhil et al . , 1996a; Vreugdenhil et al . , 1996b}. Analysis of kainate-upregulated genes by in si tu hybridisation indicated that one product is specifically induced in subregions of the hippocampus (see also below) during kainate-induced seizures but not by administration of sub-treshhold doses of kainate (data not shown) . We have cloned the corresponding cDNA encompassing 4746 bp with a stretch of 41 adenosine's at the 3' end and a classical poly- adenylation signal AATAAA present 20 bp upstream of the polyA tail . Northern blot analysis of hippocampal total RNA derived from a kainic acid-treated rat (see later) resulted in the identification of a 4950 bases-long transcript indicating the cloning of a nearly full-length cDNA. Open reading frame (ORF) analysis demonstrated the presence of many small potential peptide/protein sequences. To determine the most likely candidate we have cloned the homologous cDNA in mouse (data not shown) and compared the potential ORFs of mouse and rat. The only conserved ORF is located at the extreme 5 ' -end and encodes a peptide of 55 amino acids with a calculated pi of 4.69 (see Figure 1A) . A remarkable feature of the peptide is the presence of 12 serine residues and 7 proline residues. No apparent consensus signal peptide or transmembrane regions were identified. Post-translational motifs were searched for by PROSITE {Bairoch, 1993} and suggested phosphorylation sites at amino acid T17, S20 and S33 by protein kinase C and S45 by casein kinase (see Figure 1) , showing functional significance of the peptide in signal transduction pathways. Searches of both protein and DNA databases did not reveal significant homology of the 3 ' 4600 bp with any known sequence. In complete contrast, the remaining 5' end shared 100% sequence identity with candidate plasticity gene 16 (cpgl6; Genbank accession NR U78857) . As yet, no literature reporting the structure encoded by cpgl6 is available. To verify the sequence of cpgl6 and to study its possible relationship with our cDNA we have cloned by PCR a 2031 bp cDNA clone, called CaMK-VI (see below) by using cpgl6 specific oligonucleotides. DNA sequence analysis confirmed the cpgl6 sequence except that an additional 74 nucleotides are inserted in CaMK-VI at position 1273 of the original cpgl6 clone. This causes a frame shift and an in frame stopcodon 130 nucleotides downstream of the point of insertion and thus results in a complete different carboxy terminus than predicted in the cpglδ cDNA clone. The putative human homologue of cpgl6, KIAA0369 ({Nagase et al . , 1997} (Genbank accession NR #AB002367) predicts a protein which is identical to the carboxy-terminus of by the CaMK-VI clone. Therefore, we conclude that our CaMK-VI clone is authentic and represents an expressed transcript species in the hippocampus . CaMK-VI- contains an ORF of 1299 bp encoding a 422 amino-acid long protein which contains all of the amino acids and motifs which are characteristic for the superfamily of CaM kinases {234}. The 267 amino acids encompassing the catalytic domain exhibit 40-45% sequence identity with the catalytic domains of other CaMKs while the regulatory domains are less conserved (10-35% amino acid sequence identity) . These figures are well in line with those reported for other members of the CaMK family {Nairn and Picciotto, 1994; Hanson and Schulman, 1992; Haribabu et al . , 1995}. In particular, the structural organisation is reminiscent of the CaMK-IV protein in that a catalytic kinase domain is preceded by an approximately 60 amino acid long serine-rich N-terminal extension. Though the overall sequence identity is low (18%) , 17 serine residues are present in CaMK-VI, five of which can be aligned with serine residues of CaMK-IV. It is in this N- terminal extension that the structure of serine-rich CARP overlaps with CaMK-VI . We have concluded that CaMK-VI is a novel member of the CaMK family. Therefore, we have called this clone CaMK-VI . Alignment of the CaMK-VI cDNA clone with the cDNA clone identified by DD gives identical sequences of the first 147 bp while no homologous regions were found in the remaining parts (see figure 1) . The sequences diverge at a DNA motif resembling exon-exon boundaries (AGGA and AGGG) suggesting that our cDNA clone and CaMK-VI are derived by alternative splicing of the same gene. At the protein level, the amino- terminal 38 amino acids are identical; of the remaining 17 amino acids only 4 are identical, 3 of which are serine residues. We propose to term the 55 amino acid peptide encoded by our cDNA clone CaMKVI -related peptide (CARP) . In addition to CaMK-VI, CARP has 70% sequence identity with human doublecortin, a brain specific gene which has recently been implicated in X-linked lissencephaly and the doublecortex syndrome and which is thought to function as a signalling protein {des Portes et al . , 1998; Gleeson et al . , 1998}. " =Two of the four kinase phosphorylation sites, i.e. T17 and S30 are conserved. Interestingly, the carboxy-terminal 17 amino acids of CARP which are not homologous to CaMK-VI shares high amino acid sequence identity (82%) with doublecortin. In addition, the length of the carboxy terminal corresponds precisely with that of doublecortin suggesting a common evolutionary origin of the last coding exon for CARP and doublecortin. Expression of CARP and CaMK-VI in the rat hippocampus . The identical 5 ' -ends of the CARP and CaMK-VI cDNAs suggests a similar transcription regulation of both transcripts during kainate-induced seizures. To study this and to identify the length and number of CARP and CaMK-VI transcripts, Northern blot analysis was performed using total RNA derived from hippocampi of vehicle-treated animals and animals showing kainate-induced seizures. Nearly no CARP transcript was detectable in vehicle-treated animals (see figure 3, CARP, lane 1) . However, a dramatic 30 fold induction of a CARP RNA species ( 4.9 kb; see figure 3, CARP, lane 2) was found in animals with kainate-induced seizures. In addition, two minor transcripts of approximately 8.3 kb and 4.0 kb were observed. Surprisingly, however, the expression of CaMK-VI differed from that of CARP in that no clear upregulation was seen after kainic acid treatment. Six different CaMK-VI transcripts, one major species with a length of 5.0 kb and five minor ( 8.3 kb, 7.0 kb, 4.0 kb, 3.4 kb and 1.4 kb) were detected in both vehicle-treated and kainic acid-treated animals (see figure 3, CaMK-VI, lane 1 and 2, see also table I) . Ethidium bromide staining of the gel indicated differences in the amount of RNA loaded in the different lanes (data not shown) . This was confirmed by hybridisation with the GAPDH probe (see figure 3, bottom panels) . After correction for differences in the amount of RNA, no clear difference was observed in the expression levels of five of the six CaMK-VI transcripts after kainic acid-treatment (see table I) . However, one CaMK-VI transcript with a length of 3.4 kb " ^ as upregulated after kainate- induced seizures by a factor 2.5 (see table I). In conclusion, these experiments show that at least six different CaMK-VI transcripts are present in hippocampus, of which one is differentially regulated by kainic-acid treatment. In contrast, CARP transcript levels are very low in hippocampus under normal conditions, while kainic-acid treatment gives rise to a dramatic induction of in particular a 4.9 kb CARP transcript. To study the cellular localisation of CARP and CaMK-VI mRNAs and to confirm our Northern blot analysis we have used in situ hybridisation. In accordance with our Northern blot analysis, CARP mRNA was not detected in the brain of vehicle treated animals (see figure 4) . Kainate-induced seizures, however, led to induction of CARP mRNA in the hippocampus within 3 hours, but not in any other part of the brain (see Figure 4) . CARP mRNA was prominently present in the dentate gyrus and to a lesser extent in the pyramidal layers CA1 and CA2. CARP expression was not detected in CA3. This CARP mRNA induction is in line with our DD results {Vreugdenhil et al . , 1996a} and occurs in discrete regions of the rat hippocampus after kainate-induced seizures. In accordance with our Northern blot analysis CaMK-VI is expressed at similar levels in both vehicle-treated animals and animals with kainate- induced seizures. Highest expression was found in the dentate gyrus while the signal was less in CA1 and CA2. In contrast to CARP, CaMK-VI mRNA was also detected in the CA3 region. In conclusion, our Northern blot analysis and in situ hybridisation experiments showed differential regulation of CARP and CaMK-VI transcripts by kainate-induced seizures. CARP mRNA is normally below detection levels but is dramatically induced by seizure activity in the hippocampus, in particular in the dentate gyrus. CaMK-VI expression is already found under steady state conditions and this expression is not affected by seizure activity. Our in βi tu hybridisation experiments confirm our Northern blot analysis and show that CARP is expressed only in the dentate gyrus and pyramidal neurones of CA1 and CA2. This cell-specific expression of CARP is reminiscent of the restricted expression pattern of the transcripts generated by the CaMK-IV gene. In contrast to the wide distribution of other CaMK mRNA species, the expression of the CaMK-IV gene is highly restricted to specific neuronal cell populations {Sakagami and Kondo, 1993; Sakagami and Kondo, 1996} T- lymphocytes {Hanissian et al . , 1993; Marklund et al . , 1994; Gringhuis et al . , 1997} and germ cells {Sun and Means, 1995, Sun et al . , 1995}. This suggests that CaMK-IV and VI may form a distinct group within the superfamily of CaMKs characterised by a restricted expression, serine rich N- termini involved in auto-inhibition and alternative splicing of their corresponding genes resulting in completely different proteins/peptides . In conclusion, we have cloned and identified a cDNA clone, called CARP which is specifically upregulated by kainate- induced seizures and which is likely generated by alternative splicing of a putative CaMK gene. Expression of CARP may result in a peptide which modulate kinase activity. Our findings further substantiate a important role for kinases in the course of kainate-induced seizures. We postulate a model in which calcium overload leads to overactivation of kinases. This triggers CARP expression which, through a negative feedback action, restores kinase activity. The cloning of CARP and related cDNAs opens up the possibility to test this hypothesis . Figure legend . Figrure 1 . Alignment of the 5' end of CARP and CaMK-VI cDNA sequences and their predicted amino acid sequences and of the carboxy- terminus of the predicted human doublecortin amino acid sequence. The potential exon-exon boundary is indicated by an closed arrow. Serine residues are shown in bold. Putative phosphorylation sites are shown by asterisks. Figure 2. Structure and alignment the predicted rat CaMK-VI, CaMK-IV CARP and human doublecortin and KIAA0369 proteins. A: Alignment of the predicted primary structure of CaMK-VI with rat β-CaMK-IV. The putative catalytic domain is indicated with a solid line above the sequences; the regulatory domain is boxed. Lys 99 of CaMK-IV and Lys 112 of CaMK-VI involved in ATP binding, and Thr 244 of CaMK-IV and the corresponding Thr 239 of CaMK-VI, which are thought to be crucial for activation of the kinases by phosphorylation are shown in bold. The GTPXXXAPE motif characterising Ser/Thr kinases is found at position 227 to 234 in CaMK-IV and position 242 to 250 in CaMK-VI and is shown in italics. B: Schematic representation and alignment of CARP, CaMK-VI, CaMK-IV, doublecortin and KIAA0369. The different functional domains are boxed and indicated below the alignment. Percentage of amino acid sequence identity is indicated between the alignments. For further details: see text. Figrure 3 . Expression of CARP and CaMK-VI in the rat hippocampus as determined by Northern blot analysis. Total RNA was isolated from the hippocampus of a vehicle-treated rat (lane 1) and kainic acid treated rat (lane 2) . The blots were probed with 32 P-labelled CARP (left panel) and CaMK-VI (right panel) labelled DNA probes and exposed to Kodak X-OMAT AR films. To correct for differences in RNA quantity and quality, blots were reprobed with a GAPDH cDNA probe (shown at the bottom of both panels) . The position of RNA markers and their molecular weights in bases are indicated by arrows. Figure 4. In si tu hybridisation analysis of CARP and CaMK-VI in the rat hippocampus, panel I shows a section of a vehicle-treated animal and panel II shows a brain section derived from an animal with kainate-induced seizures. An asterisk in panel II indicates the CA3 region lacking CARP expression. Further are indicated: the pyramidal layers CA1 and CA2 , and the dentate gyrus (DG) . Control experiments using radiolabelled sense R*NA probe didn't give any signal above background (data not shown) . Table I The effect of kainic acid administration on CARP and CaMK-VI mRNA levels. Hybridisation signals were quantified using an Olympus image analysis system equipped with a Cue CCD camera. CARP and CaMK-VI signals were corrected by signals obtained from the GAPDH probe. Numbers given in the table represent the signals obtained after kainic acid administration divided by the signals obtained after vehicle treatment. As no signal for the CARP transcripts of 8.3 kb and 4.0 kb was detected in the vehicle-treated animals their induction was not determined (nd) . REFERENCES Bairoch A (1993) The PROSITE dictionary of sites and patterns in proteins, its current status. Nucleic Acids Res 21:3097- 3103. Buckmaster PS, Dudek FE (1997) Neuron loss, granule cell axon reorganization, and functional changes in the dentate gyrus of epileptic kainate-treated rats. J Comp Neurol 385:385-404. Chatila T, Anderson KA, Ho N, Means AR (1996) A unique phosphorylation-dependent mechanism for the activation of Ca2+/calmodulin-dependent protein kinase type IV/GR. J Biol Chem 27 * 1:21542-21548. des Portes V, Pinard JM, Billuart P, Vinet MC, Koulakoff A, Carrie A, Gelot A, Dupuis E, Motte J, Berwald-Netter Y, Catala M, Kahn A, Beldjord C, Chelly J (1998) A novel CNS gene required for neuronal migration and involved in X- linked subcortical laminar heterotopia and lissencephaly syndrome. Cell 92:51-61. Dobyns WB, Truwit CL (1995) Lissencephaly and other malformations of cortical development: 1995 update. Neuropediatrics 26:132-147. Frohman MA, Dush MK, Martin GR (1988) Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. Proc Natl Acad Sci U S A 85:8998-9002. Gass P, Herdegen T, Bravo R, Kiessling M (1994) High induction threshold for transcription factor KROX-20 in the rat brain: partial co-expression with heat shock protein 70 following limbic seizures. Brain Res Mol Brain Res 23:292- 298. Gass P, Bruehl C, Herdegen T, Kiessling M, Lutzenburg M, Witte OW (1997) Induction of FOS and JUN proteins during focal epilepsy: congruences with and differences to [14C] deoxyglucose metabolism. Brain Res Mol Brain Res 46:177- 184. Gleeson JG, Allen KM, Fox JW, Lamperti ED, Berkovic S, Scheffer I, Cooper EC, Dobyns WB, Minnerath SR, Ross ME, Walsh CA (1998) Doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein. Cell 92:63-72. GringHuris SI, de Leij LF, Wayman GA, Tokumitsu H, Vellenga E (1997) The Ca2+/calmodulin-dependent kinase type IV is involved in the CD5- mediated signaling pathway in human T lymphocytes. J Biol Chem 272:31809-31820. Hanissian SH, Frangakis M, Bland MM, Jawahar S, Chatila TA (1993) Expression of a Ca2+/calmodulin-dependent protein kinase, CaM kinase- Gr, in human T lymphocytes. Regulation of kinase activity by T cell receptor signaling. J Biol Chem 268:20055-20063. Hanson PI, Schulman H (1992) Inhibitory autophosphorylation of multifunctional Ca2+/calmodulin- dependent protein kinase analyzed by site-directed mutagenesis. J Biol Chem 267:17216- 17224. Haribabu B, Hook SS, Selbert MA, Goldstein EG, Tomhave ED, Edelman AM, Snyderman R, Means AR (1995) Human calcium- calmodulin dependent protein kinase I: cDNA cloning, domain structure and activation by phosphorylation at threonine-177 by calcium-calmodulin dependent protein kinase I kinase. EMBO J 14:3679-3686. Herdegen T, Sandkuhler J, Gass P, Kiessling M, Bravo R, Zimmermann M (1993) JUN, FOS, KROX, and CREB transcription factor proteins in the rat cortex: basal expression and induction by spreading depression and epileptic seizures. J Comp Neurol 333:271-288. Herdegen T, Blume A, Buschmann T, Georgakopoulos E, Winter C, Schmid W, Hsieh TF, Zimmermann M, Gass P (1997) Expression of activating transcription factor-2, serum response factor and cAMP/Ca response element binding protein in the adult rat brain following generalized seizures, nerve fibre lesion and ultraviolet irradiation. Neuroscience 81:199-212. Hughes * PE, Young D, Preston KM, Yan Q, Dragunow M (1998) Differential regulation by MK801 of immediate-early genes, brain- derived neurotrophic factor and trk receptor mRNA induced by a kindling after-discharge. Brain Res Mol Brain Res 53:138-151. Marklund U, Larsson N, Brattsand G, Osterman O, Chatila TA, Gullberg M (1994) Serine 16 of oncoprotein 18 is a major cytosolic target for the Ca2+/calmodulin-dependent kinase-Gr. Eur J Biochem 225:53-60. Mathern GW, Leite JP, Babb TL, Pretorius JK, Kuhlman PA, Mendoza D, Fried I, Sakamoto AC, Assirati JA, Adelson PD, Peacock WJ (1996) Aberrant hippocampal mossy fiber sprouting correlates with greater NMDAR2 receptor staining. Neuroreport 7:1029-1035. McNamara JO, Puranam RS (1998) Epilepsy genetics: an abundance of riches for biologists. Curr Biol 8:R168-R170. Means AR, Cruzalegui F, LeMagueresse B, Needleman DS, Slaughter GR, Ono T (1991) A novel Ca2+/calmodulin-dependent protein kinase and a male germ cell- specific calmodulin- binding protein are derived from the same gene. Mol Cell Biol 11:3960-3971. Means AR, Ribar TJ, Kane CD, Hook SS, Anderson KA (1997) Regulation and properties of the rat Ca2+/calmodulindependent protein kinase IV gene and its protein products . Recent Prog Horm Res 52:389-406; discus. Meijer OC, de Kloet ER (1994) Corticosterone suppresses the expression of 5-HT1A receptor mRNA in rat dentate gyrus. Eur J Pharmacol 266:255-261. Morimoto K, Sato K, Kashihara K, Hayabara T (1997) Increased levels * of mRNA for beta- but not alpha-subunit of calmodulin kinase II following kindled seizures. Brain Res Bull 43:375- 380. Nagase T, Ishikawa K, Nakaj ima D (1998) Prediction of the coding sequences of unidentified human genes: The complete sequence of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res 14:141-150. Nairn AC, Picciotto MR (1994) Calcium/calmodulin-dependent protein kinases. Semin Cancer Biol 5:295-303. Parent JM, Lowenstein DH (1997) Mossy fiber reorganization in the epileptic hippocampus. Curr Opin Neurol 10:103-109. Parent JM, Yu TW, Leibowitz RT, Geschwind DH, Sloviter RS, Lowenstein DH (1997) Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus. J Neurosci 17:3727-3738. Perlin JB, Churn SB, Lothman EW, DeLorenzo RJ (1992) Loss of type II calcium/calmodulin-dependent kinase activity correlates with stages of development of electrographic seizures in status epilepticus in rat. Epilepsy Res 11:111- 118. Sakagami H, Kondo H (1993) Differential expression of mRNAs encoding gamma and delta subunits of Ca2+/calmodulin- dependent protein kinase type II (CaM kinase II) in the mature and postnatally developing rat brain. Brain Res Mol Brain Res 20 : 51-63. Sakagami H, Kondo H (1993) Cloning and sequencing of a gene encoding the beta polypeptide of Ca2+/calmodulin-dependent protein kinase IV and its expression confined to the mature cerebeliar granule cells. Brain Res Mol Brain Res 19:215-218. Sakagami H, Kondo H (1996) Immunohistochemical localization of Ca2+/calmodulin-dependent protein kinase type IV in the mature and developing rat retina. Brain Res 719:154-160. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, (second edition) . New York: Cold Spring Harbor Laboratory Press. Stefani A, Spadoni F, Siniscalchi A, Bernardi G (1996) Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol 307:113-116. Sun Z, Means AR (1995) An intron facilitates activation of the calspermin gene by the testis- specific transcription factor CREM tau [published erratum appears in 1995 Nov 24;270(47) :28494] . J Biol Chem 270:20962-20967. Sun Z, Means RL, LeMagueresse B, Means AR (1995) Organization and analysis of the complete rat calmodulin-dependent protein kinase IV gene. J Biol Chem 270:29507-29514. Veeranna , Amin ND, Ahn NG, Jaffe H, Winters CA, Grant P, Pant HC (1998) Mitogen-activated protein kinases (Erkl,2) phosphorylate Lys-Ser-Pro (KSP) repeats in neurofilament proteins NF-H and NF-M. J Neurosci 18:4008-4021. von Campe G, Spencer DD, de Lanerolle NC (1997) Morphology of dentate granule cells in the human epileptogenic hippocampus. Hippocampus 7:472-488. von Wegerer J, Hesslinger B, Berger M, Walden J (1997) A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol 7:77-81. Vreugdenhil E, de Jong J, Busscher JS, de Kloet ER (1996) Kainic acid-induced gene expression in the rat hippocampus is severely affected by adrenalectomy. Neurosci Lett 212:75-78. Vreugdenhil E, de Jong J, Schaaf MJ, Meijer OC, Busscher J, Vuijst C, de Kloet ER (1996) Molecular dissection of corticosteroid action in the rat hippocampus. Application of the differential display techniques. J Mol Neurosci 7:135- 146. Wasterlain CG, Bronstein JM, Morin AM, Dwyer BE, Sankar R (1992) Translocation and autophosphorylation of brain calmodulin kinase II in status epilepticus. Epilepsy Res Suppl 9:231-238. Table 1

Claims: CLAIMS 1. A mammalian calcium/calmodulin dependent protein kinase (CaMK-VI) which in the rat comprises the sequence MLELIEVNGTPGSQLSTPRSGKSPSPSPTSPGSLRKQRISQHGGSSTSLSSTKVCSSMDEN DGPGEEESDEGFQIPATITERYKVGRTIGDGNFAWKECIERSTAREYALKIIKKSKCRGK EHMIQNEVSILRRVKHPNIVLLIEEMDVPTELYLVMELVKGGDLFDAITSTSKYTERDASG MLYNLASAIKYLHSLNIVHRDIKPENLLVYEHQDGSKSLKLGDFGLATIVDGPLYTVCGTP TYVAPEIIAETGYGLKVDIWAAGVITYILLCGFPPFRGSGDDQEVLFDQILMGQVDFPSPY WDNVSDSAKELINMMLLVNVDQRFSAVQVLEHPWVNDDGLPENEHQLSVAGKIKKHFNTGP KPSSTAAGVSVIAPDHGFTIKRSGSLDYYQQPGMYWIRPPLLIRRGRFSDEDATRM or a specific and/or active fragment or derivative thereof. 2. A, mammalian protein kinase according to claim 1 which is at least partially encoded by at least a specific part of the following DNA sequence CTCTGGCTCTTGGCTATTGTCAGGTCAAACACTAAGACTGTGTCCATGTTAGAACTCATAG AAGTTAATGGAACCCCTGGCAGTCAGCTCTCCACTCCGCGCTCCGGCAAGTCACCAAGTCC ATCGCCCACCAGCCCAGGAAGCCTGCGGAAGCAGAGGATCTCTCAACATGGCGGCTCCTCC ACTTCACTTTCATCCACAAAAGTCTGCAGCTCAATGGATGAGAACGATGGCCCTGGGGAAG AAGAGTCCGACGAAGGTTTCCAGATTCCTGCCACAATAACAGAGAGATACAAAGTCGGGAG AACAATAGGAGATGGAAATTTCGCTGTTGTCAAGGAATGTATAGAGAGGTCGACTGCTCGG GAGTATGCCCTGAAAATTATCAAGAAAAGTAAATGCCGAGGCAAAGAACACATGATCCAAA ACGAGGTCTCCATCTTAAGGAGAGTGAAGCATCCGAACATTGTTCTCCTGATTGAAGAGAT GGATGTGCCGACTGAACTATATCTTGTAATGGAGTTAGTAAAGGGTGGAGACCTTTTCGAT GCCATCACTTCCACTAGCAAATACACAGAGCGGGATGCCAGTGGGATGCTGTACAACCTGG CCAGTGCCATTAAATACCTGCACAGCCTGAACATCGTCCATCGTGACATCAAGCCAGAGAA CCTGCTGGTGTATGAGCACCAGGATGGCAGTAAGTCACTCAAGTTGGGTGACTTTGGCCTG GCCACAATTGTCGATGGCCCCCTGTACACAGTCTGTGGCACCCCAACTTATGTGGCTCCAG AAATCATTGCAGAGACTGGATATGGCCTCAAGGTGGACATCTGGGCAGCTGGCGTGATCAC TTATATCCTGTTGTGTGGTTTCCCTCCATTCCGTGGAAGTGGGGATGACCAGGAGGTGCTT TTTGACCAGATCTTGATGGGCCAAGTGGACTTTCCATCTCCGTATTGGGACAATGTGTCAG ATTCTGCTAAGGAGCTCATCAACATGATGCTGTTGGTTAACGTGGACCAGAGATTTTCAGC CGTGCAAGTCCTTGAGCACCCCTGGGTTAACGATGATGGCCTCCCAGAAAATGAACATCAG CTGTCAGTAGCTGGCAAGATCAAGAAGCATTTCAACACGGGCCCCAAGCCGAGCAGCACGG CAGCTGGAGTTTCTGTAATAGCACCGGACCACGGGTTTACCATCAAGAGATCAGGGTCTTT GGACTACTACCAACAACCAGGAATGTATTGGATAAGACCACCGCTCTTGATAAGGAGAGGC AGGTTTTCCGACGAAGACGCAACCAGGATGTGAGGGGCCGGTACAAGGCACAGCCAGCTCC ACCAGAACTCAACTCGGAATCAGAAGACTACTCCCCCAGCTCCTCTGAGACTGTCCGCTCC CCCAATTCGCCCTTTTAATAAGACCCCTTCACTCGAAGTCCTAGCTTAACCCTTTAAGACT CTGAGATTCCCCCTCCCCCCAAACTTCTGTAAAACAGGTTCATCTGATCTACCTAGCACTC AGTGCTGAACGGCAGAACAGAAAGTATATTTCGGGTACCTTTGTAGCAAGTTCCCTTTACT GAATGAGAAGGCATGTGGTGTTTGTGACAACGGTAATTTGCTGCTAATAGGGGTCCTTAAA GGGTTGAGGCTAATTTGCGATTTTTTTTCTTTTAACATAGAAGTAACGAATGTTTTCATCA GTCAGACTAGGATCTGCAGTATGTAACATAGCACATGTTAGCCCTCTGAGTGCATAGAATT TGCTTGAGAATCCTTGCTGGGGAATTTTTCAGACCCTTGAGTGTATTCACACATATTTCTT GATTTTACTGCAGACCAAGGGGCGTCATTGAGACCCAAAATGTCCACCCAAGAAGAGTATT GGGGAATGACACATTGCCAATTCTTCTCAGTGGGCTTAGACAATGACGGGTTCTACAGCAT CAGCAGATGCACCCCTCCTTCTTAGCCATCTTATGAAGAAGGGAAGTCCCTTTCCCTACAT AGTAAGCTGCAGAGCCTTCTCTGCTCTGATTGGAGGGAGTTAAGGTTTGTGGCTGCCTATC CCAAGTGATCGACAGTGTCTCTCC . 3. A mammalian calcium/calmodulin dependent protein kinase related peptide (CARP) which in the rat has the amino acid sequence MLELIEVNGTPGSQLSTPRSGKSPSPSPTSPGSLRKQRDLYRPLSSDDLDSGDSV or a derivative or a specific and/or active fragment thereof. 4. A mammalian calcium/calmodulin dependent protein kinase related peptide (CARP) according to claim 3, which is at least partially encoded by at least a specific part of the following DNA sequence GGCTATTGTCAGGTCAAACACTAAGACTGTGTCCATGTTAGAACTCATAGAAGTTAATGGA ACCCCTGGCAGTCAGCTCTCCACTCCGCGCTCCGGCAAGTCACCAAGTCCATCGCCCACCA GCCCAGGAAGCCTGCGGAAGCAGAGGGACCTGTACCGCCCTCTCTCGTCGGATGATTTGGA CTCAGGAGACTCAGTGTAAAAGACACAGTGGAGCGATGTGTATGGTTTGTGATGGGATCAA GGTTTCCCATTTCCTAAGCAAGCATCTAACAGCAAAATACACAAAAGAGTTTTGCATAAGC AATTAAATTATACAAAAGCAAGAGTGCAGACATTTTCTACTCGGCGGTATTCTTTGAAAGA AAAAAAAAACTTTTTTAAAGCATCTCCTCCATTTGATGTAACCGAGGAGAGTTTGAATACA ATATTTGTTCATCACTGAGGATTTTATGACTAAGGTCTGGTTCCAGATAAATTTCATATAT GACTCCAATATTAAGTACAAGAATCACCCTAACGATCCAGCATTATGGAGTCACCATTTCT ATAAATGAGCCTGCTTTTTAATCAGTAAGTAGATATATAAATACAATTTTTCTGTACTTAG TATCTTTTACCTTTTTAGTTTAAATTTTTTAAAAAAATCAGACAGCTAATTAGTTATTTCA TTGCAAAATAACATAAAAGAATCTCTTCAGGATTTTTTATTTGAGTGAATACGTCTGAAGG GGAGTGGAGGAACTCCGTAAGAGACGTCTCCCAGAGACCAACATTAGGCAGCGAGAACGTT TCTGGTTTTTTTTTTTTTTTTTTTTGTTTTTGTTTTTTGCCACATGGATTTTCTTTTCCCA GATTTTTATAAAAATAGTTTCAACTACATGGAAACATGAATAACTTGGCATTATTATTAAT TTTATAATGGTTCCCAACAGCAACAACAGTATATATATCTTTTTCAAGTGTGTAAAGTTTT TTGACCTAAAACAAATGGGACTTGTACTGTTTTTCAAAAAATAAACTCAGTTTGAGAATTG GAATTCTTCTACACAGAGCTTGTACGTTGGGCCTCCAGGTAGCTAAACTCCATTCTGATCA TCCTGCATCCCGTTGTTTGGGATATCTTCACATGCAAAACTCCTTTTGTGTCAAACCGAGT GTGTCTATGATTATAACCCACTGTTAAAATTAACCTACTAATTCTTCTCCTTTAGTCCTCT ACTTTCAAAAGCGTGAGTCAGCTTTGCTTAAATGTAAAACAGTTATTTTTTAAATCTAAAT GTTAGAAATCAATGTGTACGGTGTATTGTATTTAGACCATACCCGTGACCGTTTCTTTTTA CTAGCTCAAACACTAACAATTTAAGACTTACAAAGACATGGGTTTTATATTCGCCAGGCTT GACATATCTCAGTAGGGTGACAGATTTAAAATGTATGGTGCCATTTGGAGCCTTTTACTTG AGATTTCTTTCAAATTTCACTTGAAAACATTTTGAAAATGCCTGATTCAAGATGGAGAGGA GTCGCCTTGTCATACGGTCTCAAATGTTATTGATTTATTTCTCTCAGTAGACTGTTCGACT AGCAATT ^ TTTCCCATCTGGTTTATCGTTACCTGTGCTAGCATCTCACTTGACAAGTGAATA AAATATTCCAACTGAAAAAAGAAAAATAAGACCTCCAGGCAACCTACCAGCATTTGAAAAG TTAGCCGAGTGATAATTAGTGCCTCATAACCCTGCCTGTTAGAGAGGAGAGGGCACTTCTT TGGCGTGTTATTTGAGAACTGCAGACTGATCCCTCCATCTTGAAAGCACAGAGAATGATCA TACCTGTTCCAGACTTCGGATTTTAAAACTGTTTCCAATAGACACGAACAGAGACTCCTGC TGAGATCAAAGGGCCGCTTTGTCTTTAGCTGAAACAGTAAACATCTGGGAGGATGCTGTGC TGCCTGTTGGAGTGTTACGTCTTTGTAAGATGCATTGCTTAATATAGTCCAACCCGTAAAA GATTAGTACAGATTTGACTAACCTGTCAAAAAATGCAATGAAAGCAGTGGGTCAGATGGTC CAGAACAAAACATAAATTCCAGTAATTTCAACTCCCCTATGAAGTCAATCTTATGGACGAC TACTGCTAGGAGAAACCTAATAAATGTTATCTGCTATAAAAATCGTGGCTTTGTTTAGACA CAGCATAGAGTAGACTTGGACTAATTGCCAGTAGGTATTGTGGCCAACTTTCCATTCAAGC AGTTCCAGAGAGATGCAATCCCATGGCATTTCATCCTGGAACATACGATTTTTATTAAAGG ATTGTTCAAGGGCCATATATCTCATTTACTTTTGAAACTAAAGTCCCTCTGAGATTGAAAC AACACACCCTGAGATCTCTTTCTATGCACGGAATAATTCTATTATCCAAAAGCAGAGTTTT TGAACATCCAAGCAGCCCACCAGGTCATTAGTAAAGACCCAATGGGCAATTAGCAGTCACT CAAGACGTGGCTGCTTTTAGAATCCTTCTAACATCATTAGTCGCTGAACTCTAAAAATGAC CTTCTGAGGAAAGAGCTCCAGCCAACAAAAGCCACATGCTTTTCTCTCACTGATAAAGCCT CTGCTGTGTTGACCTTTCAGGCCTTTGCATGTATGGTTACATTTTTTTAGACATACCTAGA AAGAAAGATGCTATAAAGAGTCCCCTGCTTTCAGCATTTTATGAGCTAAAACCCTAGTGAT GCACAAAATGTGTTGCTCTGCGTGAACTCCGAAGCCATGTGGGAAAGTCATTGTCATTTCA GCAGAAGGTCTGTACTCTTGTAGGTTTCTAAACCGGAAGTTTGTGCTCCACCTATATGTAC GCATGCCTGCAATGCACACATGAGGTCACCTTAACATGTCAAGATCTGATCCCGTTGTCTG CCAACCCCAGAGCAGCTCTGACACCTATGCTCCCCTGCCAAGCAGCGAGGGCACTCGCCCT CCCCTTCCTTGCAGCCGCACCGAGCTGTACTTTTGTTTCCATTTAAAAGAACTGAATTCCA AAAGCCTCGTTTTAAAAAAGCAATTGGGAATGAAAATACATAAGAATAATCCTAAAAGATA AATCCATATATTTAACCTGTTGAACTACTAGGTTTTTTTTTTCTTTTCCTGGTGGCCATAT ATCTATACAGGTGTGTAGGTGTGCCTA CATGAATATCTGTGTTTGTATATAGAACATGAAGAATAAAGGATGATATTTGTGATATGGT CTTATAAGTTACTGGCTCCTGTAGAATTAACTGTGAAGCTTTATGTGATAAAGTTGTGACG TATGTATTAGTTGGCACATGTTTAAGCTCAAAACAAGTTGGCTAAATTATCATGAAGCAGT ACCAACTGTTCACGGGTACGAATTTATCCAAGACCGATTGGAATCCAGACAAACAAAAAAA TTGAAGTCCAAGCAAATCCAATCTTACAGTGATTGATAAATGTAAATACTCATTGATGTTT TCACTGTAAATTCTTGATGCTCAGCCAGTAATCTGACAGAATGCAGTGACACTTTCCTGTT GTGTGTGTACTGATGACTACAGCGATTATCAATGGGAAATTCACCAAACAAACTGATTTCT AGACTTGTGGACAGTTGAGTGTTTGTGCTGAAATAAAAGTAGAAAAGGTCAAAGTAAATTC GGTTTGAAGCCTTGTTATGAAGCCAGACAACATGTAAGGCCATGCTGTGTGTCCTTTTTAT AAACTG'PTTTGGAGACACTTGCTGTGTGTGTGCATGTGTGTCTACATGAGTGTATACACAC TTGAAAATGCTTATTGACTCAAGTTCACTGTCTGTATACATCTGTGCCTATCTGCATTGGT CTGGCCAGCGCCTCTAACTGTGCATGGTAGTGACAGCCCTGTGTGATTGGATGAACCCACA GAAAAATAGTGTGGAAATCAGAGCTGCGTCAAACTCATTATAACAATTGCCTGATATAGCA TATTAAATTGTCAGCTGAAAAACGTTTGTAATGTTGTGCCTGTAACATGTGTAGGGAAAAC TGGAAAATCTGAGGCCCTCACTATAATTTTAAGGGTGCATGACATGTGGTGTCTTTAAAGA TGTATCTTATTGTAATAAAAGGTGATGGATAAATTCTGAGGTAGCGTAAGTGAAGCATGAA ACGCTAGGTGTTTGTATTATATATGGCCACACAATATTTTTGAAGGCAGGGTAGTAAATGT TTGAAGGTTAATAGGCAAAGAATATGGAAGTTAATTTTACTGTGATGTGTTTTTGAGGTGT TTTACACATTGCCAGACAAGGAACTTAGTTCCTGTTTCCCCCCTGGGACTCTTTGAAACAC TATGAATGTTACAAAGTTGGATTTTCTTTATAAAGGTCGCAAACCATTTGCAGTTGGAGTT GCTTGGATGTATAGTCTCCTCTTTGGGGAAAAAAACCACTTTGGTATTAAAATGGTTTAAG CACTAATACATTGGGAAATACGTCGTCTGAGGCCATCTGCAGACATCTGTAGAGATGAGAA CTAATGAAATGTGTTACTGAACTACCCAGTTTTGATAGCTTCCATGCCTCTCTGCTGTAGT CTCCTCGAAAATGCTGTACCTTGTGTTTCACATGCAACCATGTTACTCTCTCCCGAACTTA CCTTTGTGACACTTAGCAGCTTAGCCAAACCACGTAATAAACAGGAAGAACTGCCAAAAAA AAAAAAAAAAAAAAAAAAAAAA. 5. A recombinant and/or isolated nucleic acid molecule encoding at least a specific and/or active part of a mammalian calcium/calmodulin dependent protein kinase (CaMK- VI) . 6. A recombinant and/or isolated nucleic acid molecule encoding at least a specific and/or active part of a mammalian calcium/calmodulin dependent protein kinase related peptide (CARP) . 7. A cloning and/or expression vector comprising an isolated and/or recombinant nucleic acid molecule according to claim 5 or 6. 8. A mammalian host cell comprising a recombinant and/or isolated nucleic acid according to claim 5 or 6 or a vector according to claim 7. 9. A mammalian calcium/calmodulin dependent protein kinase related peptide (CARP) for use as a pharmaceutical. 10. Use of a mammalian calcium/calmodulin dependent protein kinase related peptide (CARP) in the preparation of a medicament for the treatment and/or prevention of seizures and/or "damage to the central nervous system, in particular the hippocampus. 11. A method for down regulating calcium/calmodulin dependent protein kinase activity in cells comprising providing said cells with a mammalian calcium/calmodulin dependent protein kinase related peptide (CARP) according to claim 3 or 4.

Inventors: VREUGDENHIL ERNO, VREUGDENHIL, ERNO
Applicants: UNIV LEIDEN, VREUGDENHIL ERNO, UNIVERSITEIT LEIDEN, VREUGDENHIL, ERNO
Application year: 1999
Main classification: C12N15
IPC codes: A61K38, C12N9, C12N15